Previous 10 | Next 10 |
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, November 12, 2019 to report its third quarter 2019 financial results and provide...
SY-5609 Shows Robust Anti-Tumor Activity in Lung, Breast and Ovarian Cancer Models Deeper and More Sustained Responses Associated with RB Pathway Alterations Preclinical Data Support Planned Clinical Trial Strategy for SY-5609; Phase 1 Initiation Expected Q1 2020 Syros Pharma...
Thinly traded micro cap Syros Pharmaceuticals ( SYRS -4.8% ) slips on average volume on the heels of update results from its ongoing 40-subject Phase 2 clinical trial evaluating lead drug SY-1425, combined with chemo agent azacitidine, in newly diagnosed patients with relapsed/refra...
62% Composite Complete Response Rate, with 82% of Patients Achieving or Maintaining Transfusion Independence Data Support RARA as the Optimal Predictive Biomarker for Patient Selection Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the ...
Investment thesis: Biotechnology investors work on the assumption that news surrounding assets in clinical development impact company valuation significantly. Our analysis suggests that focusing on earlier events, such as Phase 2 and 3 data release, represents a stronger short-term, cataly...
Thursday was a good day on Wall Street, as investors were pleased to see many high-profile companies in the U.S. report positive earnings results. Geopolitical concerns also worked in the stock market's favor, with the U.K. and the European Union apparently agreeing to a deal that would allow Br...
Prioritizing Development of SY-5609, Its Oral CDK7 Inhibitor, and Discontinuing Further Development of SY-1365, Its Intravenous CDK7 Inhibitor Expects to Initiate Phase 1 Trial of SY-5609 in First Quarter of 2020 Management to Host Conference Call at 8:30 a.m. ET Today Syros...
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Financial Officer, Joseph J. Ferra, will present a corporate overview at the 2019 Wedbush PacGrow Healthcare Conference. Details are as follows: ...
Syros Pharmaceuticals (SYRS) Q2 2019 Earnings Conference Call August 1, 2019 08:30 ET Company Participants Naomi Aoki - Investor Relations Nancy Simonian - Chief Executive Officer Joe Ferra - Chief Financial Officer David Roth - Chief Medical Officer Eric Olson - Chief Scient...
The following slide deck was published by Syros Pharmaceuticals, Inc. in conjunction with their 2019 Q2 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
Syros Pharmaceuticals Inc. Company Name:
SYRS Stock Symbol:
NASDAQ Market:
Syros Pharmaceuticals Inc. Website:
-- Pivotal Complete Response (CR) Data from SELECT-MDS-1 Phase 3 Trial Expected by Mid-4Q24 -- -- Additional Data from SELECT-AML-1 Phase 2 Trial Expected in September 2024-- -- Management to Host Conference Call at 8:30 AM ET Today -- Syros Pharmaceuticals (NA...
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, July 31, 2024 to report its s...
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...